Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032084 | 1.00 | CYP3A4 (0.53) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6281798 | 0.93 | CYP3A4 (0.46) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL13647531 | 0.92 | CYP3A4 (0.53) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4336874 | 0.89 | CYP3A4 (0.50) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL5650468 | 0.84 | CYP3A4 (0.41) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6284315 | 0.81 | CYP3A4 (0.69) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6278233 | 0.81 | CYP3A4 (0.69) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL3961272 | 0.81 | CYP3A4 (0.53) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4038742 | 0.81 | CYP3A4 (0.51) | CYP3A4 | |
| SCHEMBL5353655 | 0.81 | CYP3A4 (0.51) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1806346-B1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS INC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-7271169-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070191390-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ZABLOCKI JEFF | 2007-08-16 | — | — | US | disclosed |
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1567525-B1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS INC (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1789407-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-7208496-B2 | Treatment of cardiovascular diseases and diabetes; {4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[4-(trifluoromethyl)phenyl]thiocarboxamide for example; fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1644345-A1 | UREA DERIVATIVES OF PIPERAZINES AND PIPERIDINES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2006029179-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060052605-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2006-03-09 | — | — | US | disclosed |
| EP-1567525-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20050049254-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2005-03-03 | — | — | US | disclosed |
| WO-2005000826-A1 | UREA DERIVATIVES OF PIPERAZINES AND PIPERIDINES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004052887-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049254-A1 | Substituted heterocyclic compounds | KCNH1, KCNJ2, SCN5A | CYP3A4 1273/4885CYP1A2 1003/4885CYP2C9 1115/4885 |
| US-20060052605-A1 | Substituted heterocyclic compounds | KCNH1, KCNJ2, KCNJ1 | CYP3A4 1120/4885CYP1A2 1121/4885CYP2C9 1149/4885 |
| US-20070191390-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, SDHA, COQ8A | CYP3A4 598/4885CYP1A2 782/4885CYP2C9 414/4885 |
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | CYP3A4 655/4885CYP1A2 882/4885CYP2C9 467/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | CYP3A4 598/4885CYP1A2 782/4885CYP2C9 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.